Migraine Physical Function Impact Diary (MPFID)

The Migraine Physical Function Impact Diary (MPFID) is a 13-item self-report questionnaire, developed to measure the subjective impact of migraine on physical functioning (everyday activities and physical impairment) in the past 24 hours. It is intended for use in adults (age 18 or older) with episodic migraine (EM) or chronic migraine (CM), with or without aura. The diary was developed using methods consistent with the regulatory guidance on patient-reported outcome (PRO) measures to support label claims about the benefit of treatments¹.

The MPFID was designed to be completed every day to capture the day-to-day variability of the impact of migraine, on migraine and non-migraine days.

The MPFID was conceptually designed to capture both ‘acts’ and ‘tasks’ associated with the impact of migraine on functioning². The MPFID includes multiple domains to assess the impact of migraine on physical functioning:

Impact on Everyday Activities (EA)
Physical Impairment (PI)
Overall Impact on Everyday Activities

¹Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Reg. 2009;74:65132-65133.
²World Health Organization. International Classification of Functioning, Disability and Health. ICF. Geneva: World Health Organization. 2001.

Continue scrolling to find out more about:

Obtaining a license to use the MPFID

Translations available

Resources and references

The Impact on Everyday Activities (EA) domain includes 7 items and generates a domain score addressing impacts on everyday activities, such as household chores, activities outside the home, and activities requiring concentration

The Physical Impairment (PI) domain includes 5 items and generates a domain score addressing impacts on physical function, such as moving the head or body and getting out of bed

Overall Impact on Everyday Activities is a standalone question assessing the global impact of migraine on doing usual activities

Licensing Information

Evidera is the contracted agency approved by the MPFID copyright holder (Amgen Inc.) to license and distribute the MPFID for use. Our responsibility includes the protection of the integrity of the MPFID as it is distributed for use, including development of translations, and adaptations.

License to Use the MPFID

A user agreement is required for all requests to use the MPFID in research. Use is granted for a single study only. Fees for licensure vary depending on the type of user making the request and nature of the research. To inquire about terms and fees for licensure to use the MPFID, please click on your affiliation below for the correct form to submit with your inquiry and an Evidera project manager will get back to you with information relevant to your needs.

Academia or not-for-profit use Pharmaceutical or commercial use

Translations Available

Current lists of the available languages can be found below:

Available translations

If you need a translation that is not on this list:

All translation work must be conducted by Evidera using their preferred vendors who have a history with the work on this clinical outcome assessment (COA)
Standardized methods for COA translation are followed and certification letters are provided
Add your language needs to the information form you submit, and you will be provided with a cost estimate and timeline with our reply to the details of your project

Resources Available

MPFID Research Presentations and Publications

The MPFID is supported by professional publications and scientific presentations.

MPFID Publications and Presentations

If you have any questions or would like to reach out directly regarding the MPFID, please do not hesitate to contact us:

View all COAs available